JP5517454B2 - Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 - Google Patents

Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 Download PDF

Info

Publication number
JP5517454B2
JP5517454B2 JP2008533792A JP2008533792A JP5517454B2 JP 5517454 B2 JP5517454 B2 JP 5517454B2 JP 2008533792 A JP2008533792 A JP 2008533792A JP 2008533792 A JP2008533792 A JP 2008533792A JP 5517454 B2 JP5517454 B2 JP 5517454B2
Authority
JP
Japan
Prior art keywords
acid
cyclosporine
agent
hcv
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008533792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510129A (ja
JP2009510129A5 (enExample
Inventor
レンウィクク ホウクク ダビド
Original Assignee
スシネキス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スシネキス インク filed Critical スシネキス インク
Publication of JP2009510129A publication Critical patent/JP2009510129A/ja
Publication of JP2009510129A5 publication Critical patent/JP2009510129A5/ja
Application granted granted Critical
Publication of JP5517454B2 publication Critical patent/JP5517454B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2008533792A 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 Expired - Fee Related JP5517454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72267905P 2005-09-30 2005-09-30
US60/722,679 2005-09-30
US78754906P 2006-03-29 2006-03-29
US60/787,549 2006-03-29
PCT/US2006/038823 WO2007041632A2 (en) 2005-09-30 2006-10-02 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Publications (3)

Publication Number Publication Date
JP2009510129A JP2009510129A (ja) 2009-03-12
JP2009510129A5 JP2009510129A5 (enExample) 2009-11-19
JP5517454B2 true JP5517454B2 (ja) 2014-06-11

Family

ID=37906852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533792A Expired - Fee Related JP5517454B2 (ja) 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物

Country Status (13)

Country Link
US (1) US7754685B2 (enExample)
EP (1) EP1933859A2 (enExample)
JP (1) JP5517454B2 (enExample)
KR (1) KR20080059270A (enExample)
CN (1) CN105169369B (enExample)
AU (1) AU2006299426B2 (enExample)
BR (1) BRPI0616476A2 (enExample)
CA (1) CA2623865A1 (enExample)
IL (1) IL190478A0 (enExample)
NZ (1) NZ567262A (enExample)
RU (1) RU2440822C2 (enExample)
WO (1) WO2007041632A2 (enExample)
ZA (1) ZA200803493B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
AU2010203660A1 (en) * 2009-01-07 2011-07-28 Scynexis, Inc Combination of a cyclosporine derivative and nucleosides for treating HCV
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
JP2014520835A (ja) 2011-07-15 2014-08-25 ビーエーエスエフ ソシエタス・ヨーロピア 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体ｉを使用した有害生物防除方法
RU2639388C1 (ru) * 2016-10-11 2017-12-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Композиция для терапии вирусного гепатита С
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
AU2021256222A1 (en) * 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683049B2 (en) * 1993-03-31 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Cholestasis ameliorant
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
NZ315324A (en) * 1995-07-17 1999-10-28 Chem Ag C Cyclosporin derivatives with anti-hiv effect
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
WO1999065933A1 (en) * 1998-06-12 1999-12-23 C-Chem Ag Novel cyclosporins
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
EP0982035B1 (en) * 1998-08-18 2004-03-31 Panacea Biotec Limited Cyclosporin composition comprising an hydrophilic carrier
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
CZ303213B6 (cs) * 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
KR100718371B1 (ko) * 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
AP2005003213A0 (en) * 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2008506648A (ja) 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｃ型肝炎（ｈｃｖ）処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用
US20060025267A1 (en) * 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
PT1793844E (pt) * 2004-10-01 2011-03-10 Debiopharm Sa Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
RU2007128098A (ru) 2004-12-23 2009-01-27 Новартис АГ (CH) Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
CA2623864C (en) * 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
US7576057B2 (en) * 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes

Also Published As

Publication number Publication date
WO2007041632A3 (en) 2007-12-13
RU2440822C2 (ru) 2012-01-27
RU2008117157A (ru) 2009-11-10
US20070173440A1 (en) 2007-07-26
IL190478A0 (en) 2008-11-03
NZ567262A (en) 2011-12-22
BRPI0616476A2 (pt) 2011-06-21
CN105169369B (zh) 2019-10-18
AU2006299426A1 (en) 2007-04-12
WO2007041632A2 (en) 2007-04-12
AU2006299426B2 (en) 2012-07-26
KR20080059270A (ko) 2008-06-26
ZA200803493B (en) 2009-12-30
US7754685B2 (en) 2010-07-13
JP2009510129A (ja) 2009-03-12
CN105169369A (zh) 2015-12-23
CA2623865A1 (en) 2007-04-12
EP1933859A2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
JP5517454B2 (ja) Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
JP5139065B2 (ja) Ｃ型肝炎感染の治療及び予防のための３−エーテル及び３−チオエーテル置換シクロスポリン誘導体
JP5322647B2 (ja) ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7576057B2 (en) Cyclic peptides
JP5820722B2 (ja) シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20080255038A1 (en) Pharmaceutical compositions
US20110144005A1 (en) Novel cyclic peptides
US20090306033A1 (en) Novel cyclic peptides
KR20120125610A (ko) 시클로스포린 유사체
CN104870007A (zh) 新的抗病毒大环化合物
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CN101316606B (zh) 治疗和预防丙型肝炎感染的方法和药物组合物
HK1125953A (en) Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
HK1108703B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140401

R150 Certificate of patent or registration of utility model

Ref document number: 5517454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees